This appraisal was funded by the NIHR Health Technology Assessment programme and we were commissioned to act as the Evidence Review Group (ERG). The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the clinical and cost effectiveness of the drug for the first-line treatment of advanced and/or metastatic renal cell carcinoma. The ERG appraised the manufacturer submission and submitted a report to the NICE Appraisal Committee. The ERG also independently searched for relevant evidence and modified the manufacturer's decision analytic model to examine the impact of altering some of the key assumptions. We found that for progression-free survival (PFS), there was a statistically significant longer survival for pazopanib compared with placebo. The Appraisal Committee concluded that pazopanib should be recommended as a first-line treatment option for advanced renal cell carcinoma.
Andrew Elders; firstname.lastname@example.org
Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L (2013). Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: A Single Technology Appraisal. PharmacoEconomics. 31(1), 15-24.
Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L. (2010). Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: A Single Technology Appraisal. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen. http://www.nets.nihr.ac.uk/projects/hta/0822001